Blood Test AKR1B10 for Early Warning of Liver Cancer in Cirrhosis Patients
Studies a blood test, AKR1B10, to detect early liver cancer in people with cirrhosis.
Plain-language title generated from the registry record
Registry title: The Role of Serum AKR1B10 in Early Warning of Hepatocellular Carcinoma in Cirrhosis Patients
Key facts
- Where
- Hengyang, ChinaSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults aged 18-75 with liver cirrhosis and chronic hepatitis who do not have liver cancer. It studies whether a blood test, AKR1B10, can give early warning of liver cancer.
- Age
- 18 to 75 years
- Sex
- Men and women can join
- Disease stage
- Liver cirrhosis and chronic hepatitis; no diagnosis of hepatocellular carcinoma (HCC)
- Earlier treatment
- Has not taken part in another clinical trial in the last 3 months
Main reasons for not taking part
- Pregnancy or breastfeeding
- Already diagnosed with hepatocellular carcinoma (HCC)
- Severe disease of the heart, brain, lungs, kidneys or blood-forming system
- Incomplete clinical, blood test or imaging records
- Taking part in another clinical trial now or in the last 3 months
Read by machine on 12 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
Source: NCT07147335, who can take part
Where in China
- University of South ChinaHengyang, ChinaContact: Xi Zeng, PhDTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- The First Affiliated Hospital of University of South China
- Trial code
- NCT07147335
- Record updated
- 29 August 2025
- Original description
Hepatocellular carcinoma (HCC) is a globally prevalent malignancy. In its characteristic "chronic hepatitis-liver cirrhosis-HCC" progression trilogy, patients with cirrhosis demonstrate a 5-year HCC incidence rate of 3%-5%, yet effective monitoring strategies remain lacking. Current early diagnosis relies on the combination of imaging techniques and serum alpha-fetoprotein (AFP), but AFP measurements are frequently confounded by pregnancy and liver diseases, resulting in suboptimal sensitivity and specificity. In recent years, novel tumor biomarkers such as AKR1B10 (Aldo-keto reductase family 1 member B10) have been examined. This multicenter prospective cohort study aims to validate the predictive value of serum AKR1B10 for malignant transformation in cirrhosis-HCC progression, and evaluate its combined efficacy with existing risk prediction models, ultimately establishing a high-sensitivity early diagnostic strategy for clinical implementation.Read full original descriptionShow less
The Role of Serum AKR1B10 in Early Warning of Hepatocellular Carcinoma in Cirrhosis Patients ------ Risk Early Warning and Follow-up Study
Hepatocellular carcinoma (HCC) is a globally prevalent malignancy. In its characteristic "chronic hepatitis-liver cirrhosis-HCC" progression trilogy, patients with cirrhosis demonstrate a 5-year HCC incidence rate of 3%-5%, yet effective monitoring strategies remain lacking. Current early diagnosis relies on the combination of imaging techniques and serum alpha-fetoprotein (AFP), but AFP measurements are frequently confounded by pregnancy and liver diseases, resulting in suboptimal sensitivity and specificity. In recent years, novel tumor biomarkers such as AKR1B10 (Aldo-keto reductase family 1 member B10) have been examined. This multicenter prospective cohort study aims to validate the predictive value of serum AKR1B10 for malignant transformation in cirrhosis-HCC progression, and evaluate its combined efficacy with existing risk prediction models, ultimately establishing a high-sensitivity early diagnostic strategy for clinical implementation.
Inclusion: Meets diagnostic criteria for liver cirrhosis and chronic hepatitis; Aged 18-75 years, regardless of gender; Willing to participate in the study and provides signed informed consent; Has not participated in other clinical trials within the last 3 months.
Exclusion: Lost to follow-up prior to reaching the observational endpoints; Concurrent severe systemic diseases (e.g., involving cardiovascular, cerebral, pulmonary, renal, or hematopoietic systems); Aged <18 years or >75 years; Pregnancy or lactation; Incomplete clinical data, serological or imaging records; Current or recent (within 3 months) participation in other clinical trials; Diagnosed with hepatocellular carcinoma (HCC).